Mirantus Health is a Berlin based health technology company focused on improving access to specialist eye care. Its model combines digital screening, mobile services and a distributed network of ophthalmologists to support early detection in regions where access to specialists is limited. The company is active within a wider European context marked by rising demand for ophthalmology and ongoing workforce shortages.
Mirantus Health has successfully secured €5.5 million in funding to significantly scale its software platform, mira, across the DACH region (Germany, Austria, and Switzerland). The company is tackling the growing strain on ophthalmological care, a challenge marked by a retiring workforce and increasing demand for consultations, by creating additional low-threshold access points.
Funding History
Seed Funding
Mirantus Health recently completed a seed round of 5.5 million euros. The round included investment from Revent, Redstone, Entrepreneur First, Noaber, Arve Capital and several individual backers with experience in digital health. The funding is being used to scale the mira platform and extend service coverage across Germany, Austria and Switzerland. The goal is to increase active screening locations from around two hundred to more than one thousand by 2027.
Earlier Funding Stages
Public information on earlier stages is limited. Mirantus began with initial backing that supported the development of its core screening technology, the formation of its clinical review network and the early deployment of mobile screening units. These foundations enabled the company to build its first operational network and expand towards a more structured investment phase. Additional details may be released as the company progresses through future rounds.
Company Background
Mirantus Health was founded in 2022 with the aim of improving early detection and access to eye care services. The company focuses on underserved regions, where waiting times for specialist appointments can be long and access to ophthalmologists is uneven. Its model provides a standardised screening pathway that links opticians, mobile units and remote specialists.
Leadership and Team Structure
Mirantus Health was founded by Dominik Pederzani. He leads the organisation’s strategic direction, guides product development and shapes partnerships with clinical and operational stakeholders. The wider team brings together experience in digital health engineering, clinical coordination and operational management to support the company’s distributed screening model.
Technology and Operating Model
The mira Screening Platform
Mirantus Health uses its mira platform to support eye screening delivered by trained opticians. The platform guides examinations such as retinal imaging, intraocular pressure measurement, slit lamp assessment, refraction data capture and visual acuity testing. Once complete, data is securely transmitted to ophthalmologists for review.
Distributed Clinical Review Network
More than four hundred ophthalmologists form the clinical review network. They analyse screening data and return reports within twenty four to forty eight hours. These reports indicate whether any abnormalities have been detected and whether a patient should seek further assessment. The process supports early detection but does not provide a full diagnosis.
Mobile Screening Units
The company operates mobile units known as Augenmobile. These units bring screening services to rural communities and nursing homes. They follow the same digital workflow as fixed locations, allowing consistent screening regardless of location.
Market Context and Challenges
European ophthalmology is experiencing significant pressure. An ageing population is increasing the number of people who require specialist care, while many ophthalmologists are approaching retirement. As a result, waiting lists can be long in some regions. These challenges have created a need for screening models that reduce bottlenecks and make early detection more accessible.
Mirantus Health contributes to this shift by providing screening points that do not require an ophthalmologist to be present on site. This allows specialists to focus on cases that require direct clinical intervention.
Current Operations and Expansion Plans
Mirantus Health is operating across Germany and is expanding into Austria and Switzerland. The company plans to grow from around two hundred active locations to more than one thousand by 2027. Its approach involves working with optical retailers, care facilities and healthcare partners to create consistent screening pathways across regions.
Technology Impact on Care Pathways
The screening model gives patients faster access to early detection and helps reduce delays that may arise from long specialist waiting times. Although the screening report is not a diagnosis, it provides a clear indication of whether further medical evaluation is needed. This supports earlier intervention, reduces pressure on clinics and improves overall care coordination.